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In recent years, there has been growing interest in clarifying the pathogenesis of some chronic diseases, 
such as obesity and type 2 diabetes mellitus. Metabolic alterations in these diseases are characterized by 
chronic hyperglycemia and insulin resistance. Studies have demonstrated the participation of minerals in 
the pathogenesis of insulin resistance, more specifically their involvement in the synthesis and regulation 
of insulin. Selenium is an anti-inflammatory and antioxidant micronutrient that is essential for the activity 
of selenoproteins. Two selenoproteins (glutathione peroxidase and selenoprotein P) are known to be 
involved in the insulin signaling pathway. The aim of this review is to provide an update on the role of 
selenium in insulin resistance mechanisms. Evidence shows that adequate concentrations of selenium 
play a key role in the secretion and action of insulin, but an excess of selenium in the body is associated 
with the pathogenesis of insulin resistance and the development of diabetes mellitus.
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INTRODUCTION
In recent years, the pathogenesis of some chronic 
diseases has attracted interest, such as obesity and type 2 
diabetes mellitus. Metabolic alterations in these diseases 
are characterized by chronic hyperglycemia and insulin 
resistance (Rains, Jain, 2011; Steinbrenner, 2013).
Recent studies have attempted to elucidate the 
molecular alterations involved in the development of 
insulin resistance. These include reductions in the number 
and activity of relevant receptors in peripheral tissues, 
and changes to intracellular insulin signaling pathways 
(Tencerova et al., 2015; Winnier et al., 2015). Accordingly, 
minerals have been the subject of several studies, focusing 
specifically on their involvement in the synthesis and 
regulation of insulin (Cruz et al., 2014; Garcia et al., 2013).
Selenium is an anti-inflammatory and antioxidant 
micronutrient essential for the activity of selenoproteins, 
such as glutathione peroxidase (GPx) and selenoprotein 
P (Sepp). These enzymes are also involved in insulin 
regulation (Cominetti et al., 2011; Steinbrenner et al., 
2013; Wei et al., 2014; Zou et al., 2016). Several studies 
have revealed selenium to be an insulin-mimetic, because 
it plays roles in the regulation of enzymes in the insulin 
signaling cascade, the expression of lipogenic enzymes, 
and in carbohydrate metabolism in the liver (Chen et al., 
2015; Iizuka et al., 2010; Mao, Teng, 2013).
However, it has been emphasized that chronic 
ingestion of large amounts of selenium promotes the 
formation of antioxidant selenoproteins, leading to 
reduced concentrations of reactive oxygen species, which 
are required in physiological amounts for insulin signaling 
(Labunskyy et al., 2011; Wang et al., 2014; Zhou et al., 
2015).
Given that insulin resistance is a key metabolic 
disorder that can result in the development of chronic 
diseases such as type 2 diabetes mellitus, and that selenium 
participates in the prevention of this disease, we have 
reviewed the participation of this micronutrient in insulin 
resistance. 
Etiologic factors of insulin resistance
Insulin has a crucial function in glucose homeostasis; 
it regulates the balance between glucose production by the 
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liver, and glucose uptake by muscle and adipose tissue. 
In myocytes and adipocytes, insulin regulates glucose 
transport by controlling the translocation of a glucose 
transporter (GLUT4) to the plasma membrane (Bruce, 
Hanson, 2010; Kim, Feldman, 2015).
The insulin receptor is a tetramer composed of 
two extracellular α-subunits and two transmembrane 
β-subunits. The action of insulin is initiated through 
binding to the α-subunits, which alters the conformation 
of the β-subunits. This results in autophosphorylation and 
activation of its tyrosine kinase function. The β-subunit 
can autophosphorylate, and it can phosphorylate other 
proteins or intracellular substrates, such as insulin receptor 
substrate 1 (IRS-1), insulin receptor substrate 2 (IRS-2), 
and the Src homology collagen (Shc) family of proteins 
(Hirabara et al., 2014; Litvinova et al., 2014).
The action of insulin is mediated by three main 
signaling cascades: the phosphatidyl inositol 3-kinase 
(PI3K)/protein kinase B (Akt) pathway, the Cbl associated 
protein (CAP)/Cbl pathway, and the Ras/mitogen-activated 
protein kinase (MAPK) pathway. These pathways regulate 
relevant cellular processes, such as glucose uptake, protein 
synthesis, and the expression of genes involved in cellular 
proliferation and differentiation (Litvinova et al., 2014).
Phosphorylation of IRS-1 (a process performed by 
various protein kinases, particularly PI3K) results in the 
formation of binding sites for proteins containing the Src 
homology 2 domain (SH2). This activation is required for 
stimulation of glucose transport by insulin, and is sufficient 
to induce GLUT4 translocation to the plasma membrane, 
at least partially. After phosphorylation by PI3K, IRS-
1 begins to activate other cytoplasmic substrates, such 
as serine kinases, protein kinase B (Akt), and atypical 
isoforms of protein kinase C (aPKCζ and aPKCι/λ). Once 
phosphorylated, these proteins participate in insulin signal 
transduction pathways for glucose transport (Kwon, 
Pessin, 2013). 
In addition to PI3K activation, other signals are 
required for insulin-stimulated glucose transport. In the 
second pathway, activation of the insulin receptor leads 
to phosphorylation of the Cbl oncogene. In most insulin-
sensitive tissues, Cbl is associated with the adapter protein 
CAP. After phosphorylation, the Cbl-CAP complex 
migrates to the cell membrane and interacts with the 
CrkII protein, which in turn is associated with the C3G 
protein. C3G is a nucleotide exchanger that catalyzes 
the conversion of GDP to GTP in the TC10 protein, thus 
activating it. Once activated, TC10 generates a second 
signal for translocation of the GLUT4 protein, in parallel 
with the activation of PI3K (Hirabara et al., 2012; 
Litvinova et al., 2014).
In a similar manner to other growth factors, 
insulin stimulates MAPK. This pathway begins with 
the phosphorylation of IRS and/or Shc proteins, which 
interact with growth factor receptor binding protein 2 
(Grb2). The latter is constitutively associated with Son 
of Sevenless (SOS), which is a protein that exchanges 
GDP for GTP in Ras (a GTP-binding switch protein), thus 
activating it. Activation of Ras requires the participation of 
Src homology phosphatase 2 (SHP2). Once activated, Ras 
stimulates serine phosphorylation of the MAPK cascade, 
which promotes cellular proliferation and/or differentiation. 
Pharmacological blockade of this pathway prevents the 
effect of insulin on cell growth, but has no effect on insulin’s 
metabolic properties (Hirabara et al., 2012).
The term insulin resistance refers to the reduced 
sensitivity of peripheral tissues to the action of insulin, 
which is caused by changes in insulin-mediated signaling 
pathways, and results in systemic hyperglycemia. Causes 
of insulin resistance include various metabolic aberrations 
that reduce the capacity of tissues to respond to insulin, 
especially in the liver, adipose tissue, and muscle 
(Tencerova et al., 2015; Winnier et al., 2015).
At various stages of insulin resistance, some tissues, 
such as skeletal muscle and adipose tissues, regulate 
GLUT4 expression differently. In the adipocytes of obese 
individuals, the concentration of GLUT4 is reduced, while 
concentrations in the skeletal muscle are normal. Since 
skeletal muscle is the main site for insulin-stimulated 
glucose consumption, changes in systemic sensitivity 
to insulin in obese and diabetic individuals cannot be 
explained by the reduced production of GLUT4. Instead, 
insulin resistance in these patients is explained by the 
low glucose uptake in skeletal muscle, which is due to 
the reduced translocation of GLUT4 from intracellular 
vesicles to the cell membrane (Muntoni, Muntoni, 2011; 
Slattery et al., 2014).
It is important to note that regulation of the cellular 
redox balance is necessary to maintain and adapt insulin 
secretion, and to promote sensitivity of the target tissues 
to insulin. In this sense, oxidative stress is related to the 
multifactorial etiology of insulin resistance, with effects 
mainly observed in skeletal muscle tissues (Steinbrenner, 
2013; Henriksen, Diamond-Stanic, Marchionne, 2011). 
Several systemic and cellular problems may contribute 
to increased production of reactive oxygen species, such as 
hyperglycemia, dyslipidemia, endoplasmic reticulum stress, 
advanced glycation end products, and lipid peroxides. These 
conditions can activate factors that are associated with 
reduced insulin action. These factors include the impairment 
of insulin signaling by phosphorylation of IRS on serine 
and threonine residues, alteration of cellular redistribution 
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of insulin signaling components, decreased transcription 
of the GLUT4 gene, and changes in mitochondrial activity 
(Henriksen, Diamond-Stanic, Marchionne, 2011; Rains, 
Jain, 2011; Steinbrenner, 2013).
In this regard, two mechanisms of reactive oxygen 
species production appear to be most relevant to the 
etiology of insulin resistance: the excess mitochondrial 
production of hydrogen peroxide (H2O2), and the increased 
activation of NADPH oxidase. Excess H2O2 production 
promotes mitochondrial dysfunction, which can affect 
insulin secretion in pancreatic β-cells. Excess H2O2 
production is also involved in insulin resistance in skeletal 
muscle, particularly among individuals with high-energy 
expenditure, such as increased lipid intake. The increase 
in NADPH oxidase activation is mediated by angiotensin 
II receptors, which generate superoxide anions and impair 
insulin signaling by disrupting the translocation of GLUT4 
(Henriksen, Diamond-Stanic, Marchionne, 2011; Rains, 
Jain, 2011).
Selenium and insulin resistance
Changes in selenium status appear to contribute 
significantly to the development of insulin resistance 
(Feng et al., 2015; Kim, Song, 2014; Pounis et al., 2014). 
Previous research has shown that dietary supplementation 
with selenium can reduce fasting serum insulin 
concentrations and the insulin resistance index (Alizadeh 
et al., 2012; Bahmani et al., 2016; Farrokhian et al., 2016). 
The main findings of studies that have investigated the 
role of selenium on insulin resistance are described in 
Tables I and II. 
TABLE I - Selenium, glycemic parameters and insulin resistance: a summary of human studies
Study Design Selenium Levels Results Ref.
Prospective cohort study
Men and women from Sweden (n = 
1925), aged > 50 years, follow-up 
of 20 years
Serum selenium 
Baseline: 75.6 ± 14.3 µg/L (range 
of 24–132.8 µg/L)
No significant associations found between serum 
selenium levels at baseline and glucometabolic 
traits (fasting blood glucose, fasting serum 
insulin, proinsulin, intravenous glucose tolerance 
test, HOMA-IRb, HOMA-Bc, and type 2 diabetes 
risk).
Gao et al., 
2014
Cross-sectional studies
Men and women from China (n = 
2242), aged = 53.0 ± 13.2 years
Urinary selenium 
Quartile 1: < 4.55 
Quartile 2: 4.55–7.49 
Quartile 3: 7.50–11.76 
Quartile 4: > 11.76
Higher fasting plasma glucose levels: quartiles 3 
and 4 vs. the lowest of urinary selenium.
ORd for diabetes compared to quartile 1: quartile 
2 [0.947 (0.599, 1.497)], quartile 3 [1.244 (0.787, 
1.968)] and quartile 4 [1.574 (0.968, 2.559)].
No significant associations with impaired fasting 
glucose risk.
Feng et al., 2015
Men and women in Korea, aged 
19–85 years 
- Group A: n = 71 visceral obese 
- Group B: n = 73 controls
Hair selenium 
Group A: 0.053 ± 0.003 mg% 
Group B: 0.055 ± 0.003 mg%
No differences in hair selenium concentrations 
between groups.
Hair selenium negatively correlated with HOMA-
IRb (r = -0.251) and insulin (r = -0.306) only in 
the viscerally obese group.
Kim, Song, 2014
Men with visceral obesity (n = 78) 
from Indonesian, median age = 37 
years
Plasma selenium 
approaching or above  
70 ng/mL
No significant correlation between selenium 
concentrations and glucose homeostatic 
parameters (fasting glucose plasma and HOMA-
IRb).
Mutakin et al., 
2013
 Women without diabetes from 
Italy (n = 6879 men and 6891 
women), aged = 53.1 ± 11.0 years)
Selenium intake 
Quartile 1: < 50 µg/day 
Quartile 2: 50–60 µg/day 
Quartile 3: 61–75 µg/day 
Quartile 4: > 75 µg/day
Dietary selenium was positively associated with 
blood glucose (p < 0.05).
Increase of 50 µg/day in dietary selenium was 
associated with increases of 0.14 (men) and 0.11 
mmol/L (women) in fasting blood glucose levels.
ORd for diabetes (highest vs. lowest quartiles): 
1.33 (1.01, 1.77) for men and 1.71 (1.17, 2.51) 
for women.
Pounis et al., 
2014
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Study Design Selenium Levels Results Ref.
Randomized double-blind placebo-controlled clinical trials
Premenopausal women with 
central obesity from Iran (n = 84), 
aged 20–50 years 
- Group A (n = 17): HDELa + 
placebo 
- Group B (n = 17): HDELa + 
arginine (5 g/day) 
- Group C (n = 17): HDELa + 
selenium (200 µg/day) 
- Group D (n = 17): HDELa + 
arginine + selenium 
- 8-week intervention
Not evaluated.
Selenium supplementation significantly lowered 
fasting concentrations of serum insulin and 
HOMA-IRb in group C.
Alizadeh et al., 
2012
Patients with diabetic nephropathy 
from Iran, aged 45–85 years 
- Group A (n = 30): 200 μg daily 
selenium supplements (selenium 
yeast) 
- Group B (n = 30): placebo 
- 12-week intervention
Not evaluated.
A decrease in serum insulin levels (p = 0.01), 
HOMA-IRb (p = 0.02), and HOMA-Bc (p = 0.009) 
as compared with the placebo.
No significant effects on fasting plasma glucose 
and quantitative insulin sensitivity check index as 
compared with the placebo.
Bahmani et al., 
2016
Men and women from France, aged 
35–60 years 
- Group A (n = 1533): antioxidant 
supplement [120 mg vitamin C, 
30 mg vitamin E, 6 mg β-carotene, 
100 µg Se (in the form of selenium-
enriched 
yeast) and 20 mg Zn)] 
- Group B (n = 1613): placebo 
- intervention for 7.5 ± 0.3 years 
Selenium plasma 
Baseline:  
Group A: 1.10 ± 0.19 (women) and 
1.15 ± 0.21 (men) mmol/LGroup 
B: 1.09 ± 0.20 (women) and 1.13 ± 
0.19 (men) mmol/L
No significant difference in age-adjusted 
mean fasting plasma glucose between groups.
Baseline plasma concentrations of selenium were 
positively (p < 0.0001) associated with fasting 
plasma glucose.
Czernichow et 
al., 2006
Patients with type 2 diabetes 
mellitus from Iran, aged 18–70 
years 
- Group A (n = 33): 200 μg daily 
selenium supplements (selenium 
yeast) 
- Group B (n = 27): placebo 
- 12-week intervention
Serum selenium 
Baseline: 42.69 µg/L (group A) and 
47.11 µg/L (group B).
After supplementation: 71.98 µg/L 
(group A) and 45.38 µg/L (group 
B).
An increase in fasting plasma glucose (p < 0.01) 
as compared with the placebo.
Faghihi et al., 
2014
Patients with type 2 diabetes 
mellitus and stable coronary heart 
disease from Iran, aged 45–85 
years 
- Group A (n = 27): 200 μg daily 
selenium supplements 
- Group B (n = 27): placebo  
- 8-week intervention
Selenium intake: no significant 
differences between groups before 
and after supplementation.
A decrease in serum insulin levels (p = 0.001), 
HOMA-IRb (p = 0.004), HOMA-Bc (p = 0.002), 
and a significant increase in QUICKIe (p = 0.02) 
as compared with the placebo.
Farrokhian et al., 
2016
aHDEL: hypocaloric diet enriched in legumes; bHOMA-IR: homeostasis model assessment of insulin resistance; cHOMA-B: homeostasis model 
assessment of β-cell function; dOR: odds ratio; eQUICKI: quantitative insulin sensitivity check index.
TABLE I - Selenium, glycemic parameters and insulin resistance: a summary of human studies (cont.)
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TABLE II - Selenium, glycemic parameters and insulin resistance: a summary of studies in cellular and non-human animal models
Study Model Selenium Treatment Main Results Ref.
Non-human animal studies
Diabetic rats (Sprague–
Dawley)
Sodium selenite (5 ppm) 
at a drinking water for 4 
weeks
- ↓ blood glucose;
- Restored the plasma level of GLP-1 to its normal range;
- ↑ GLP-1R mRNA level and restored the GLP-1R 
protein level in the liver to its normal level;
- ↓ mRNA levels of IRS-1 and restored IRS-1 protein 
level in the liver to its normal level;
- Reduced the increase in both the Raf-1a mRNA and 
protein levels in the liver.
Barakat, Moustafa, 
Bikhazi, 2012
Diabetic rats (Sprague–
Dawley)
Sodium selenite (5 ppm) 
at a drinking water for 4 
weeks
- ↑ GLP-1R and IRS-1 mRNA levels with no significant 
change in protein levels in the pancreas;
- ↑ preproinsulin mRNA levels in the pancreas;
- ↑ number of endocrine islet in the pancreatic tissue 
with restoration of normal cellularity and viable cells.
Barakat et al., 2016
Diabetic rats (Wistar)
Sodium selenite (1 ppm) 
at a 
drinking water for 2 or 4 
weeks
- ↓ serum glucose with normal range values restored 
after 4 weeks;
- ↓ HbA1Cb levels to its normal values after 4 weeks;
- ↓ hepatic activity of lactate dehydrogenase after 4 
weeks;
- ↓ hepatic activities of glucose-6-phosphatase and 
glycogen phosphorylase after 2 and 4 weeks;
- ↓ hepatic activity of levels of after 2 and 4 weeks;
- ↑ glycogen content in the liver at similar values to 
control group;
- ↑ hepatic uptake and turnover of glucose after 4 weeks.
Chen et al., 2015
Diabetic rats (Goto-
Kakizaki)
1) Daily intraperitoneal 
injections of sodium 
selenate (0.173 mg/kg 
body weight) for 14 days; 
2) Samples of isolated 
adipocytes incubated 
with 50 μL solutions of 
various concentrations 
of sodium selenate 
(final concentration 1 
μmol/L–10 mmol/L).
- The glucose uptake and the suppression of hepatic 
glucose output were similar between control rats and 
sodium selenate-treated GK rats;
- ↑ basal 2-deoxyglucose uptake in the presence of 
insulin into adipocytes;
- Glucose incorporation was potentiated by sodium 
selenate into adipocytes.
Iukuza et al., 2010
1) Rats 
2) Hepatocyte cell line 
BRL-3A 
1) Intragastric 
administration: 219 µg/
kg (Group 1) or 438 µg/
kg (Group 2) of sodium 
selenite daily for 6 weeks. 
2) Incubation with 
sodium selenite (1 µM or 
10 µM) for 36 hours
-↑ blood glucose levels (Group 2);
- Impaired glucose and insulin tolerance (Group 2);
- ↓ insulin-stimulated phosphorylation of Akt both in 
rats (Group 2) and in hepatocytes (10 µM);
- ↑expression of phosphoenolpyruvate carboxykinase 
and glucose-6-phosphate both in rats (Group 2) and in 
hepatocytes (10 µM);
- ↓ insulin-stimulated glycogen synthesis in hepatocytes 
(10 µM).
- ↑ free fatty acids content in the liver (Group 2) and in 
hepatocytes (10 µM);
- ↑ mitochondrial reactive oxygen species production in 
the liver (Group 2) and in hepatocytes (10 µM).
Wang et al., 2014
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Study Model Selenium Treatment Main Results Ref.
Female Wistar rats and its 
offspring*
Se-enriched yeast for 5 
weeks 
Group 1 (deficient): 
basal diet (12 µg/kg of 
selenium) 
Group 2 (adequate): 
basal diet + 0.3 mg/kg of 
selenium 
Group 3 (high): basal diet 
+ 3.0 mg/kg of selenium 
*The pups were fed 
the same diet as their 
respective dam.
- ↑ insulin and glucose levels on day 19 of gestation and 
day 14 postpartum, respectively (Group 3);
- Glucose tolerance and insulin resistance impaired on 
day 19 of gestation (Grupo 3);
- Offspring were glucose intolerant and insulin resistant 
(Grupo 3);
- ↓ mRNA levels of Akt2, Insrc, Irs1 and FoxO1 in liver 
of the offspring (Grupo 3);
- ↓ mRNA levels of Irs2 and Pgc-1 in muscle of the 
offspring (Grupo 3).
Zeng et al., 2012
Diabetic rats (Wistar)
Sodium selenite (1 ppm) 
at a 
drinking water for 2 or 4 
weeks
- ↓ serum glucose after 2 and 4 weeks;
- ↑ insulin levels after 2 and 4 weeks;
- Improved hepatic antioxidant status after 4 weeks;
- Overall improvement in histoarchitecture of the liver, 
with reduction of lipid deposition and lymphocytic 
infiltration.
Zou et al., 2016
Cell studies (in vitro)
1) Mouse beta-cell line 
Min6 
2) Isolated rat islets of 
Langerhans
1) Incubation with 
sodium selenite 
(30 nmol/L) for 3 hours. 
2) Incubation with 
sodium selenite 
(30 nmol/L) for 72 hours. 
- Significant 5-fold increase in GPx activity;
- 3.5-fold increase in the activity of the Ipf1d promoter 
and a 7-fold increase in the activity of the beta-cell 
specific section of this promoter;
- ↑ Ipf1 mRNA and protein levels;
- ↑ insulin mRNA levels;
- ↑ insulin content and secretion from isolated rat islets 
of Langerhans;
Campbell et al., 2008
L6C11 rat skeletal muscle 
cell line
Incubation with 1 μM 
to 100 µM of various 
selenium compounds 
(L-selenomethionine, 
sodium selenite, 
methylseleninic acid or 
sodium selenate) for 24 
hours.
- ↓ intracellular reactive oxygen species generation with 
selenite (1 μM) exhibiting the most pronounced effect 
followed by selenomethionine (10 μM);
- ↓ insulin-induced phosphorylation of Akt by selenite 
and methylseleninic acid (1 μM);
- ↓ insulin-stimulated glucose uptake by selenite (5 μM) 
and methylseleninic acid (1 μM);
-  ↑  i n s u l i n - s t i m u l a t e d  g l u c o s e  u p t a k e  b y 
selenomethionine (100 μM).
Pinto et al., 2011
aRaf1: Raf-1 proto-oncogene, serine/threonine kinase; bHbA1C: Glycated hemoglobin A1C; cInsr: insulin receptor; dIpf1: insulin promoter factor 1.
TABLE II - Selenium, glycemic parameters and insulin resistance: a summary of studies in cellular and non-human animal models 
(cont.)
Selenium’s antidiabetic action appears to result from 
its behaviour as an insulin-mimetic and as an antioxidant 
nutrient, since insulin signaling, and secretion is associated 
with the cellular redox state (Mao, Teng, 2013; Rayman, 
Stranges, 2013; Steinbrenner, 2013). In a study performed 
by Barakat, Moustafa and Bikhazi (2012), it was found 
that 4 weeks of treatment with sodium selenite (5 ppm 
in drinking water) increased mRNA and protein levels of 
glucagon-like peptide-1 receptor (GLP-1R) in the liver 
of diabetic rats, which may have favored the reduction of 
blood glucose levels. It is worth mentioning that GLP-1 
appears to reduce hepatic glucose production by promoting 
glycogen synthesis (D’Alessio, Vahl, Prigeon, 2004). 
In a subsequent study using the same experimental 
model, these researchers investigated the effects of 
selenium treatment in the pancreas of diabetic rats. 
Increases in GLP-1R, IRS-1 and preproinsulin mRNA 
levels were found. Moreover, selenium treatment 
improved the number of endocrine islets, with restoration 
of normal cellularity and viable cells in the pancreatic 
The role of selenium in insulin resistance
Braz. J. Pharm. Sci. 2018;54(1):e00139 Page 7 / 11
tissue (Barakat et al., 2016). The effects of GLP-1 on 
the biosynthesis and secretion of insulin, as well as the 
proliferation, differentiation and apoptosis of pancreatic 
β cells, are well known (Lee, Jun, 2014). In this regard, 
these results suggest a possible role of selenium in the 
physiological actions of incretin hormones.
Similarly, Campbell et al. (2008) found that 
selenium participates in insulin’s action on β-pancreatic 
cells, through its ability to regulate the gene expression 
of insulin promoter factor 1, and to increase the mRNA 
expression of insulin in the mouse beta cell line Min6. 
Selenium promotes the increased production and secretion 
of insulin in these cells.
In a study by Iukuza et al. (2010), 0.173 mg/
kg of sodium selenite (Na2SeO3) was administered 
intraperitoneally to diabetic rats for 14 days. The result 
was increased glucose uptake by peripheral tissues 
and adipocytes. This was probably due to the action of 
selenium on the insulin receptor, thus increasing sensitivity 
to insulin and alleviating hyperglycemia, for regulation of 
hepatic glucose production.
It is important to mention selenium’s role in the 
regulation of the hepatic metabolism of carbohydrates. 
Chen et al. (2015) found that the administration of 
selenium to diabetic rats (through a 1 ppm dose in their 
drinking water) increased cellular glucose uptake and 
restored the activity of glucose-6-phosphatase and 
glycogen phosphorylase (enzymes involved in the hepatic 
glucose production) to normal levels.
Pancreatic β-cells are known for their reduced 
antioxidant protection, probably due to the important 
role played by physiological concentrations of reactive 
oxygen species in insulin signaling pathways. Research 
has revealed lower expression of GPx selenoproteins, 
and higher expression of Sepp1 in these cells. These 
findings are suggestive of a possible role of selenium in 
the regulation of the redox state of pancreatic β-cells (Lei, 
Vatamaniuk, 2011; Steinbrenner et al., 2013).
A study by Steinbrenner et al. (2013) showed that 
Sepp1 can provide additional antioxidant protection to 
the islets of Langerhans, serving as a selenium donor 
for the function of other antioxidant selenoproteins 
such as Gpx, and participating in the protection of cell 
membranes from oxidative damage. Sepp1 is also located 
in glucagon-secreting cells. Nevertheless, elevated 
glucose concentrations (11–22 mM) appear to dysregulate 
the expression of Sepp1 in β-cells, which can reduce 
antioxidant function and trigger endocrine dysfunction.
Labunskyy et al. (2011) found that a deficiency of 
Sepp1 and methionine sulfoxide reductase 1 (MsrB1) 
in transgenic mice induces glucose intolerance and 
hyperinsulinemia. Research by Zou et al. (2016) showed 
that selenium treatment (a 1 ppm dose in drinking water) 
in diabetic rats reduces serum glucose concentration, 
lipid peroxidation, and the activity of the enzymes 
aspartate aminotransferase, alanine aminotransferase, and 
alkaline phosphatase. The authors also demonstrated that 
selenium supplementation increased the activity of major 
antioxidant enzymes, such as GPx, superoxide dismutase, 
and catalase. Figure 1 shows the participation of selenium 
in protection from insulin resistance.
On the other hand, selenium may also impair 
insulin’s action in target cells. Some studies have shown 
an association of high dietary selenium intake with 
increased risk of diabetes and insulin resistance (Table 
I and II) (Pounis et al., 2014; Stranges et al., 2007). The 
negative action of selenium on insulin signaling pathways 
appears to relate to dysregulation of the cellular redox state 
(Labunskyy et al., 2011; Wang et al., 2014).
In this context, the overexpression of antioxidant 
selenium-dependent enzymes promotes the removal 
of intracellular hydrogen peroxide, which is a reactive 
oxygen species that regulates key enzymes for insulin 
signaling. In turn, this promotes the dephosphorylation 
of the enzymes of insulin signaling, thereby inactivating 
them and changing the action of insulin (Steinbrenner, 
2013; Wang et al., 2014; Zhou, Huang, Lei, 2013). 
In particular, some investigators have described the 
inhibition of phosphorylation of specific enzymes of the 
insulin signaling pathway, such as Akt and 5’-adenosine 
monophosphate-activated protein kinase (AMPK), 
caused by the elevated expression of GPx or Sepp1. 
Sepp1 also inhibits phosphorylation of the tyrosine 
residue on hepatocyte insulin receptors, and promotes the 
phosphorylation of a serine residue in IRS-1 (Misu et al., 
2010; Steinbrenner, 2013; Wang et al., 2014).
Zeng et al. (2012) found that in rats, a diet rich in 
selenium (3.0 mg/kg per day) can induce hyperinsulinemia, 
insulin resistance, and glucose intolerance. High selenium 
intake also reduces the mRNA expression or protein levels 
of six factors that participate in insulin signaling pathways 
in the liver and muscle, and increases the activity of GPx1 
in the pancreas, liver, and erythrocytes.
Similarly, Labunskyy et al. (2011) found that 
under conditions of high selenium intake (a 0.4 ppm 
dose of sodium selenite), there is increased expression 
of the antioxidant selenoproteins GPx1 and MsrB1, and 
a positive correlation between GPx1 overexpression and 
the expression of other selenoproteins, such as SelS and 
SelT. These findings suggest that the factors described 
may participate in the impairment of insulin signaling. 
The authors suggest that the cellular dysregulation of the 
L. C. Fontenelle, M. M. Feitosa, J. B. S. Morais, J. S. Severo, T. E. C. Freitas, J. B. Beserra, G. S. Henriques, D. N. Marreiro
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redox state, caused by high selenoprotein expression, 
can compromise the protein folding of insulin and its 
receptor.
Pinto et al. (2011) demonstrated the action of 
various compounds containing selenium (sodium 
selenite, sodium selenate, selenomethionine, and 
methylseleninic acid) on insulin sensitivity in vitro 
in myocytes. The authors found that > 1 μM doses of 
sodium selenite and methylseleninic acid were capable 
of inhibiting Akt phosphorylation, and attenuated the 
glucose uptake by decreasing the concentration of 
intracellular reactive oxygen species. This result can 
be attributed to the differences in bioavailability and 
metabolism of the selenium-containing compounds.
In addition, selenium may contribute to the induction 
of insulin resistance because of its role in the metabolism 
of carbohydrates and lipids (Steinbrenner, 2013). In a 
study on mice, Wang et al. (2014) found that high doses of 
selenium (200 mg/kg) can promote increased expression 
of carboxykinase phosphoenolpyruvate and glucose-
6-phosphatase, a key enzyme for gluconeogenesis. 
The authors also found that selenium promotes the 
accumulation and metabolism of fatty acids in the liver; 
this effect is related to the increased production of reactive 
oxygen species originating from mitochondrial oxidative 
phosphorylation, and hence the development of hepatic 
insulin resistance.
In this scenario, it is noteworthy that hyperglycemia 
favors hepatic Sepp1 transcription by activating the 
forkhead box class O 1α (FoxO1α) and hepatocyte nuclear 
factor 4α (HNF-4α) transcription factors, through the 
action of peroxisomal proliferator-activated receptor 
gamma coactivator 1α (PCG-1α). These transcription 
factors bind to a functional site in the Sepp1 promoter 
and upregulate gene expression. They are also involved in 
regulating the expression of hepatic glucose metabolism 
enzymes, and it is known that insulin promotes the 
inactivation of these enzymes. Therefore, under insulin 
resistance conditions, there may be an increase in Sepp1 
concentrations concomitant with the increase in the 
activity of gluconeogenic enzymes. This situation may 
partially explain the associations between selenoprotein 
concentrations and the risk of type 2 diabetes mellitus 
(Jung et al., 2013; Mao, Teng, 2013; Steinbrenner et al., 
2011; Steinbrenner, 2013).
A study by Jung et al. (2013) showed that induction 
of diabetes in rats by palmitate increases the expression 
of Sepp1 in HepG2 cells, thereby exacerbating insulin 
FIGURE 1 - The role of selenium in protection from insulin resistance. Overall, selenium appears to improve insulin resistance 
through three mechanisms. A) Firstly, in β-pancreatic cells, selenoproteins such as Sepp1 and Gpx exert antioxidant action, thereby 
inhibiting the excessive production of reactive oxygen species, which may impair the insulin signaling pathway. Moreover, selenium 
promotes the transcription and synthesis of proinsulin, insulin promoter factor 1, and GLP-1R. In the figure, we highlight the 
participation of the GLP-1-activated protein kinase A pathway in the regulation of insulin secretion and synthesis. B) Secondly, 
in the liver, selenium influences hepatic glucose production, by regulating glucose-6-phosphatase and glycogen phosphorylase 
enzymatic activity, and increasing GLP-1R expression. C) Thirdly, in peripheral organs, selenium improves insulin sensitivity due 
to its antioxidant action. GLP-1: glucagon-like peptide 1; GLP-1R: GLP-1 receptor; GPx: glutathione peroxidase; IPF1: insulin 
promoter factor 1; IRS-1: insulin receptor substrate 1; P: phosphorylation; PKA: protein kinase A; ROS: reactive oxygen species; 
Se: selenium; Sepp1: selenoprotein P1.
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resistance. The activation of AMPK, induced by either 
salicylate or adiponectin, could reverse the increase in 
Sepp1 expression through phosphorylation of FoxO1α. 
Similar results were obtained by Takayama et al. (2014), 
wherein metformin inhibited the AMPK-mediated 
increased expression of Sepp1 in the H4IIEC3 hepatocytes 
of diabetic rats. On the other hand, coadministration of an 
AMPK antagonist reversed these results, indicating that 
this pathway can be a possible therapeutic target of insulin 
resistance and diabetes.
CONCLUSION
The action of selenium in the pathogenesis of insulin 
resistance is not fully elucidated, but our review has 
revealed that the main mechanisms involve the regulation 
of intracellular concentrations of reactive oxygen species, 
and carbohydrate and lipid metabolism. When ingested in 
sufficient amounts to maintain plasma concentrations in 
the range of 80-120 µg/L (Rayman, 2012), selenium acts as 
an antioxidant and insulin-mimetic nutrient, favoring the 
synthesis and action of insulin. However, when selenium 
intake results in plasma levels above 120 µg/L (Rayman, 
2012), the cellular redox state may become dysregulated, 
which can compromise the chemical interactions 
involved in the insulin signaling cascade. Nevertheless, 
it is noteworthy that the effects of selenium on insulin 
resistance are dependent on the chemical form (organic or 
inorganic), dose, and exposure time; these factors are not 
yet fully established. Further studies are needed to clarify 
the relation between selenium and insulin resistance in 
humans.
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